In short
This article discusses a clinical trial exploring the use of cefepime-enmetazobactam, a combination drug, in treating complicated urinary tract infections (cUTI) in children. The study aims to evaluate the drug's safety, effectiveness, and how it behaves in the bodies of young patients, from newborns to teenagers. This research is an important step in potentially expanding treatment options for children with cUTI.
At a glance
- Study Type
- Phase 2, single group
- Participants
- Children from birth to under 18 years with cUTI
- Intervention
- Cefepime-enmetazobactam combination, IV every 8 hours
- Duration
- 3-7 days of treatment, follow-up until 28 days post-treatment
- Primary Outcomes
- Pharmacokinetics (Cmax, Tmax, AUC, half-life), Safety, Tolerability
- Secondary Outcomes
- Efficacy (clinical and microbiological success rates)
What is ENMETAZOBACTAM?
ENMETAZOBACTAM is a new medication being studied for the treatment of complicated urinary tract infections (cUTIs) in children. It's actually a combination of two drugs: cefepime and enmetazobactam. This combination is also known as cefepime-enmetazobactam.
A complicated urinary tract infection is a serious infection that affects the urinary system (kidneys, bladder, ureters, and urethra). It's called "complicated" because it's harder to treat than a simple UTI, often due to underlying conditions or problems with the urinary tract.
How is it used?
ENMETAZOBACTAM is given through an intravenous (IV) line, which means it's delivered directly into the bloodstream through a vein. The medication is administered every 8 hours, and each dose is given over a period of two hours.
Who can receive this treatment?
The current study is looking at the use of ENMETAZOBACTAM in children and teenagers. Specifically, it includes:
- Children from birth (newborns) up to 18 years old
- Both boys and girls
- Patients who are in the hospital with a complicated urinary tract infection
What does the study involve?
The study is designed to help researchers understand more about how ENMETAZOBACTAM works in children's bodies and how safe it is. Here's what participants can expect:
- Treatment duration: The medication will be given for 3 to 7 days, depending on how quickly the infection improves.
- Hospital stay: Patients need to stay in the hospital at least while receiving the treatment.
- Follow-up visits: After the treatment ends, there will be several follow-up visits:
- End of Treatment visit (EOT): Right after the last dose
- Test of Cure visit (TOC): 7 days after the last dose
- Late Follow-up visit (LFU): 14 days after the last dose
- End of Study visit (EOS): 28 days after the last dose (this might be a phone call)
What are the researchers looking at?
The researchers are interested in several aspects of how ENMETAZOBACTAM works in children's bodies. They're measuring things like:
- Pharmacokinetics: This is how the drug moves through the body. It includes:
- How much of the drug gets into the bloodstream (Cmax)
- How long it takes to reach its highest level in the blood (Tmax)
- How long the drug stays in the body (half-life)
- How the body processes and removes the drug (clearance and volume of distribution)
- Safety and tolerability: This includes tracking any side effects or adverse events that occur during the study.
Safety and Side Effects
A major focus of this study is to assess the safety of ENMETAZOBACTAM in children. The researchers will be closely monitoring for any side effects or adverse events. They'll be looking at:
- How many patients experience any side effects
- How many side effects are thought to be related to the medication
- Whether any patients need to stop the treatment due to side effects
- Any serious side effects that occur
It's important to note that all medications can have side effects, and part of this study is to understand what side effects might occur with ENMETAZOBACTAM in children.
Effectiveness of the Treatment
While the main goal of this study is to understand how the drug works in children's bodies and its safety, the researchers are also looking at how well it works to treat the infection. They'll be assessing:
- Clinical response: This means checking if the symptoms of the infection have improved.
- Microbiological response: This involves testing to see if the bacteria causing the infection have been eliminated.
- Overall success rate: This combines both the clinical and microbiological responses to see how many patients have fully recovered from their infection.
The researchers will check these responses at various points during and after the treatment to see how quickly and effectively ENMETAZOBACTAM works.